PubMed Health⌕ Search

Biomedical subjects

Torben Christensen

Publications and source records attributed to Torben Christensen.

2 recordsLinked to original sources

Social network among young adults with first-episode schizophrenia spectrum disorders: results from the Danish OPUS trial.

BACKGROUND: Social network has considerable impact on physical and mental health. Patients experiencing first-episode psychosis early in adult life may experience severe problems concerning development and maintenance of their social network. METHODS: A total of 547 first-episode psychotic patients (18-45) were randomised to standard or integrated treatment, (ACT, social skills training and family intervention), and followed up at 2 years. RESULTS: Service use or psychotic symptom score did not influence the social network size, measured after the first 2 years of treatment. Small network size was associated with long duration of untreated psychosis (DUP), poor premorbid adjustment, male gender and severe negative symptoms. The number of friends at 2-year follow-up was predicted by age, A-level status, negative symptoms and number of friends at entry, while the determinants for number of family contacts were age, gender, disorganised dimension and family contacts at entry. CONCLUSIONS: Premorbid functioning, network size at entry and DUP is closely related to small social network size. The integrated psychosocial treatment programme was not sufficient to address this problem.

Adult↗

The MediChew technology platform.

A few decades ago, chewing gum was rarely considered when industry searched for an applicable delivery vehicle for an active pharmaceutical substance. Yet, the 1980s and 1990s saw gum become the most successful nicotine delivery form; unawareness changed to cautious scepticism, and today the merits of chewing gum drug delivery technologies are generally appreciated. MediChew is the registered trademark of Fertin Pharma's medical chewing gum technology platform. Based on patent-protected technologies, it offers unique taste-masking possibilities and allows control of drug molecule release. Medical chewing gum products based on these technologies are specifically suitable for convenient administration on demand, for active substances providing a topical effect in the oral cavity and throat, and for systemic delivery of drug molecules that readily cross the oromucosal membranes.

Chewing Gum↗